Faculty Bibliography

BACKGROUND:Complications of hip resurfacing arthroplasty (HRA) may require conversion to total hip arthroplasty (THA). While well-fixed acetabular components are often retained during conversion, data on implant survival and associated risks are limited. This study evaluated implant-related outcomes, survivorships, and complications in patients who undergo HRA to THA conversion with acetabular component retention. METHODS:A retrospective review of 40 patients having undergone conversion from HRA to THA was conducted. Patients were included if the original HRA acetabular component was retained, provided they had at least one year of clinical follow-up. Demographics, perioperative variables, implant characteristics, and clinical outcomes were collected via chart review. The mean time to conversion was 8.2 years (range, 0.1 to 14.2) with an average of 4.1-years of follow-up (range, 1.0 to 10.9). Common indications for conversion included metallosis (40.0%), mechanical loosening (32.5%), and periprosthetic fracture (22.5%). Most cases (97.5%) were converted to dual-mobility constructs. RESULTS:There were six patients (15.0%) who underwent subsequent reoperation following conversion, including three for infection, one for dislocation, and two for aseptic stem loosening. Kaplan-Meier analysis demonstrated an all-cause revision-free survivorship of 90.0% at one year and 81.2% at 10 years, with aseptic survivorship of 88.5% and acetabular component survivorship of 100% through final follow-up. CONCLUSION/CONCLUSIONS:Conversion of HRA to THA with retention of a well-fixed acetabular component and conversion to a dual-mobility construct provides durable survivorship up to 10 years (mean follow-up: 4.1 years). However, the rates of periprosthetic joint infection (PJI) and reoperation are more aligned with those seen in revision THA than primary THA, emphasizing the need for careful patient selection and transparent preoperative counseling. These findings highlight that while this approach can be an effective option for failed hip resurfacing, appropriate caution is warranted to mitigate the elevated risks of infection and reoperation in this cohort.

BACKGROUND:Postoperative improvement in patient-reported outcomes is a key measure of total hip arthroplasty success. The Minimum Clinically Important Difference (MCID) represents the smallest improvement perceived as beneficial. Distribution-based MCIDs have been criticized for producing thresholds smaller than anchor-based values, questioning their clinical relevance. We hypothesized they may capture early biological recovery signals associated with subsequent patient-reported outcomes and aimed to determine whether failure to achieve an early distribution-based MCID (seven to 31 days) was associated with failure to achieve a late anchor-based MCID (90 to 365 days). METHODS:This retrospective cohort study included patients undergoing primary unilateral total hip arthroplasty for osteoarthritis from January 1, 2021, to January 1, 2025, comprising 844 patients. Patients were included if they completed 'Hip disability and Osteoarthritis Outcome Score, Joint Replacement' questionnaires preoperatively, at seven to 31 days, and at 90 to 365 days. Distribution-based MCID was defined as a ≥ 7.8-point improvement, and anchor-based MCID as ≥ 23 points. Multivariable regression assessed associations between early distribution-based and late anchor-based MCID failure, adjusting for demographics and clinical factors. RESULTS:In the early period (seven to 31 days), 565 patients (67.0%) achieved the distribution-based MCID, whereas 573 (67.9%) achieved the late anchor-based MCID (90 to 365 days). Among patients who failed to attain an early distribution-based MCID, 54.1% (151 of 279) also failed the late anchor-based MCID, compared with 21.2% (120 of 565) among early achievers (P < 0.001). Early distribution-based MCID failure was a strong independent predictor of late anchor-based MCID failure (odds ratio: 2.61; 95% confidence interval: 1.85 to 3.68; P < 0.001). Higher baseline Hip disability and Osteoarthritis Outcome Score, Joint Replacement scores and facility-based discharge were also independently associated with late failure (P < 0.05). CONCLUSIONS:Failure to achieve an early distribution-based MCID is strongly associated with poor patient-reported outcomes up to one year. Early distribution-based MCID attainment may represent an important prognostic marker, enabling timely clinical intervention.

BACKGROUND:Nonmodular dual mobility (DM) articulations in total hip arthroplasty (THA) aim to reduce dislocations through a large outer bearing diameter while minimizing wear via a smaller inner bearing where most motion occurs. Although routine use remains uncommon in the United States, this construct may protect against dislocation. This study aimed to evaluate clinical outcomes of a cementless, nonmodular DM acetabular cup at a mean follow-up of two years. METHODS:We conducted a single-arm retrospective review of 604 primary, elective THAs using a cementless nonmodular DM acetabular cup between April 2017 and August 2024 at a single health system with at least 90 days of follow-up. All surgeries were performed by a single hip surgeon via posterior approach. Cases were planned using digital templating and performed with manual instruments without enabling technology. Clinical outcomes were collected, including 90-days readmission and revision rates, reasons for readmission and revision, and dislocation rates. RESULTS:At a mean follow-up of 2.0 years (range, 0.25 to 8.0), all-cause and aseptic acetabular cup implant survivorship was 99.8%. There were six revisions during the study period. There was one acetabular component (0.2%) that was revised due to cup dissociation from the pelvis. The remaining revisions included two for periprosthetic femoral fracture (0.3%), one for femoral loosening (0.2%), and two for acute periprosthetic joint infection (0.3%), none of which involved revision of the acetabular cup. There were no dislocations observed, and no patients required revision for instability. CONCLUSIONS:Cementless nonmodular DM acetabular cups offered excellent clinical outcomes in primary THA at a mean follow-up of 2.0 years, with no observed dislocations in 604 cases and high implant survivorship. These findings support the use of nonmodular DM implants as a viable option to achieve THA implant stability and durable fixation even when using a posterior approach without enabling technology.

BACKGROUND:Prolonged retention of antibiotic-loaded articulating spacers after the first stage of a two-stage revision for periprosthetic joint infection (PJI) can occur because of patient preference, surgeon preference, or medical reasons that prevent the planned second stage. Little is known about the frequency of persistent infections, mechanical complications, and functional results in patients with retained spacers. QUESTIONS/PURPOSES/OBJECTIVE:At a minimum follow-up of 2 years after spacer placement, among patients who do not undergo the second stage revision (replacement of the spacer with a definitive prosthesis of the hip or knee): (1) What was the survival of the spacer free from unplanned reoperation or removal, the cumulative incidence of symptomatic infection, and the overall (Kaplan-Meier) survivorship of the patients? (2) What is the cumulative incidence of mechanical complications (spacer fracture or dislocation)? (3) What is the ambulatory status of patients who have retained their spacers? METHODS:Between March 2011 and July 2023, a total of 111 and 152 patients underwent first-stage revision with an articulating spacer placement as part of a planned two-stage procedure for chronic PJI after THA and TKA at our institution, respectively. Of these, 21% (23 of 111) in the THA group and 24% (37 of 152) in the TKA group did not undergo the anticipated second-stage reimplantation at our institution at least 1 year after spacer placement. Among the original cohorts, 2% (2 of 111) of patients who underwent THA and 3% (4 of 152) of patients who underwent TKA subsequently underwent second-stage reimplantation at outside institutions when reviewed, leaving 19% (21 of 111) in the THA group and 22% (33 of 152) in the TKA group with retained spacers. Of the original cohorts, 7% (8 of 111) in the THA group and 5% (8 of 152) in the TKA group did not have a 2-year follow-up, leaving 12% (13 of 111) of patients with THA and 16% (25 of 152) of patients with TKA available for analysis with a minimum of 2 years of follow-up or death in this retrospective study. The median (range) follow-up from spacer placement to the latest follow-up was 5 years (2 to 11) for patients with THA and 4 years (2 to 8) for patients with TKA. In the THA cohort, the median (range) age was 72 years (59 to 86), and eight patients were female; the median BMI was 32 kg/m2, and the median Charlson comorbidity index (CCI) was 3.5. In the TKA cohort, the median (range) age was 69 years (45 to 83), 13 patients were female, the median BMI was 31 kg/m2, and the median CCI was 4. Complication data following spacer placement were obtained from the electronic medical record and by telephone follow-up when needed. Clinical symptoms (swelling, erythema, warmth, fever, drainage, sinus tract, and pain), inflammatory markers (C-reactive protein and erythrocyte sedimentation rate), available radiographic findings, and laboratory test results (including synovial fluid analysis when obtained) were reviewed for evidence of infection or spacer-related mechanical failure. Infection after the spacer placement was defined as failure when the treating surgeon determined that an unplanned return to the operating room or spacer removal was warranted, acknowledging that postoperative evaluation thresholds varied among surgeons. Spacer-related mechanical failure was defined as spacer fracture or dislocation leading to reoperation or spacer removal. Patients were classified based on whether they underwent an unplanned reoperation or spacer removal. Patients who did not undergo unplanned reoperation or spacer removal were further categorized based on use of chronic suppressive antibiotics (decisions regarding chronic antibiotic therapy were made by the treating surgeon and/or infectious disease team). Patients who underwent reoperation were those who returned to the operating room because of concerning clinical, imaging, and/or laboratory findings of infection or mechanical complications, and the treating surgeon decided to proceed with revision surgery. All reoperation decisions were made by fellowship-trained arthroplasty surgeons with high-volume experience in two-stage revision. We used a competing-risks model to estimate survival of the spacer free from unplanned reoperation or removal attributable to infection or mechanical complications (calculated as 1 minus the corresponding cumulative incidence), with death treated as a competing event. Kaplan-Meier analysis was used to estimate patient survivorship, with death as the endpoint. Mortality data were obtained from medical records and hospital databases and were confirmed by telephone follow-up with family members and public records when needed. Ambulatory status before and after spacer placement was summarized descriptively and reported only for patients with both prespacer and postspacer data available (10 THAs and 25 TKAs); no formal hypothesis testing was performed for ambulatory or functional measures. RESULTS:At 2 years of follow-up, the survival of the spacer free from unplanned reoperation or removal was 89% (95% confidence interval [CI] 80% to 99%) for patients with THA and TKA combined, the cumulative incidence of infection was 5% (95% CI 0% to 12%), and the Kaplan-Meier survivorship of the patients was 92% (95% CI 84% to 100%). The cumulative incidence of mechanical complications (spacer fracture or dislocation) was 5% (95% CI 0% to 13%). In the THA cohort (10 patients), ambulatory status before the first stage included two patients using a wheelchair, two using a walker, one using crutches, two using a cane, and three walking without assistive devices. At latest follow-up, four patients used a wheelchair, two used a walker, two used a cane, and two walked without assistive devices. In the knee cohort (25 patients), ambulatory status before the first stage included two patients using a wheelchair, five using a walker, 13 using a cane, and five walking without assistive devices. At latest follow-up, two patients used a wheelchair, five used a walker, 13 used a cane, and five walked without assistive devices. CONCLUSION/CONCLUSIONS:Retained articulating spacers can provide infection control in selected patients who do not proceed to reimplantation after first-stage spacer placement for PJI. Although infection-free spacer survival is achievable, these patients remain at risk for mechanical complications, including dislocation and fracture, as well as progressive functional decline. These risks should be clearly discussed during preoperative counseling to align expectations and support informed decision-making. Further studies are needed to refine patient selection, improve spacer durability, and standardize definitions of treatment success in PJI. LEVEL OF EVIDENCE/METHODS:Level III, case series.

BACKGROUND:This study compares clinical and functional outcomes between simultaneous hardware removal during total knee arthroplasty (TKA) and staged TKA after prior hardware removal. METHODS:We retrospectively reviewed 155 patients who had prior knee hardware and underwent elective primary TKA between 2012 and 2024 at an urban academic institution. Patients were categorized into "simultaneous" removal during TKA (n = 127) or "staged" TKA after removal (n = 28), and stratified by hardware type (minor/moderate/major). RESULTS:Simultaneous procedures involved significantly less "major hardware," single incisions, and tibial stem extensions than staged procedures (32.3 versus 78.6%, P < 0.001; 81.9 versus 100%, P = 0.007; and 0.8 versus 10.7%, P = 0.019, respectively). Hardware, particularly the major type, was more often retained or partially retained in the simultaneous group (48.0 versus 21.4%, P = 0.008). Reoperation, revision, and infection rates did not significantly differ based on timing or hardware location. Simultaneous patients had smaller 3-month Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity and Interference score reductions (-1.6 versus -9.9, P = 0.006 and +0.4 versus - 7.2, P = 0.007, respectively), but greater 2-year Knee Injury and Osteoarthritis Outcome Score for Joint Replacement improvements (+25.0 versus - 1.1, P = 0.006) compared to staged patients. Simultaneous major hardware removal demonstrated significantly greater 2-year Knee Injury and Osteoarthritis Outcome Score for Joint Replacement and PROMIS Pain Interference improvement (+32.0 versus -5.5, P = 0.001, and -6.2 versus +5.8, P = 0.027, respectively), but smaller 2-week PROMIS Pain Intensity score reduction (+2.2 versus -4.9, P = 0.050) compared to staged procedures. CONCLUSIONS:Simultaneous hardware removal during TKA led to higher retained major hardware rates and fewer single incisions than staged procedures, without increased reoperation or revision risks. Despite higher 3-month pain scores, simultaneous surgery achieved greater 2-year functional improvement, suggesting it offers advantages for select patients.

BACKGROUND:The Centers for Medicare and Medicaid Services now mandates the collection of patient-reported outcome measures (PROMs) before and after total knee arthroplasty (TKA), though their utility in predicting clinical outcomes remains unclear. This study compared the power of preoperative PROMs to predict clinical outcomes after TKA to established indices, including the Charlson Comorbidity Index and the Risk Assessment and Prediction Tool (RAPT). METHODS:We retrospectively reviewed 2,923 patients undergoing elective, primary, unilateral TKA who completed the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement and four Patient-Reported Outcomes Measurement Information System (PROMIS) domains within 90 days preoperatively. Outcomes included same-day discharge (SDD) rate, prolonged length of stay (LOS ≥ 48 hours), nonhome discharge, 90-day readmission, and revision surgery. Predictive utility was assessed using receiver operating characteristic curves (area under the curve [AUC]) and multivariable logistic regressions. RESULTS:The RAPT was the strongest predictor of SDD (AUC = 0.697), extended LOS (AUC = 0.703), and nonhome discharge (AUC = 0.877). The PROMIS Physical Health (AUC = 0.609 for SDD; 0.607 for LOS; 0.696 for discharge) and PROMIS Mental Health (AUC = 0.613; 0.610; 0.655) demonstrated modest predictive value. In adjusted models, higher PROMIS Mental Health was associated with greater odds of SDD (odds ratio (OR) = 1.027, P = 0.003) and lower odds of extended LOS (OR = 0.975, P < 0.001). Higher PROMIS Physical Health was associated with decreased odds of nonhome discharge (OR = 0.935, P = 0.017). The Charlson Comorbidity Index was the strongest predictor of 90-day readmission (AUC = 0.604) and the only significant variable in adjusted models. There were no PROMs that were significant predictors of readmission or revision. CONCLUSIONS:Preoperative PROMs are associated with some clinical outcomes following TKA, but demonstrate limited predictive power compared to established tools like the RAPT score. These findings underscore the need for more robust, outcome-aligned PROMs to improve surgical planning in a value-based care model.

BACKGROUND:Periprosthetic joint infection (PJI) remains one of the most challenging complications after total joint arthroplasty (TJA). While conventional culture remains the standard for identification of causative pathogens in PJI, rapid identification techniques such as polymerase chain reaction (PCR) are becoming increasingly popular, with little comparative data. METHODS:A retrospective review was performed on a database of consecutive patients who underwent workup for PJI at a tertiary referral center from January 1, 2023, to May 31, 2025. Patients who underwent both standard synovial fluid culture and a PCR panel on the same day were included. Synovial fluid culture was used as the reference standard, and test result concordance and turnaround time were assessed. RESULTS:Results from the PCR panel showed strong agreement with synovial fluid culture in the 225 cases analyzed, with 88% culture-positive agreement. The PCR false negatives were due to organisms not included in the PCR panel (n = six), a false-positive culture from contamination (n = one), and a patient who had a PJI due to Candida parapsilosis (n = two). When only considering true positives with organisms included in the panel, the PCR displayed a 97.1% culture-positive agreement. The panel also detected organisms in eight culture-negative cases (94.7% culture-negative agreement). Those cases each met the 2018 International Consensus Meeting definition of PJI, were treated as PJIs, and their negative culture results were hypothesized to be due to antibiotic use before culture. The panel's turnaround time (TAT) (median 8.4 hours) is significantly faster than both culture-positive (P < 0.001) (69.2 hours) and culture-negative (P < 0.001) (139.5 hours) results from synovial fluid culture. CONCLUSIONS:The high concordance between the panel and conventional culture techniques suggests that PCR may be added as an adjunctive diagnostic tool for PJI workup after TJA. Our results also suggest that PCR may be more accurate than fluid culture in patients who have current antibiotic usage. The PCR's advantage of rapid TAT is particularly helpful in the timely optimization of antibiotic therapy.

Background Metal hypersensitivity in patients undergoing total knee arthroplasty (TKA) remains a poorly defined clinical entity. This study aimed to characterize the clinical burden of metal hypersensitivity in a national database. The primary objective was to evaluate trends in metal hypersensitivity diagnosis in the general and TKA populations, as well as the TKA revision rate in patients with and without metal hypersensitivity. Secondary objectives were to identify trends in the release of "metal-sensitive" joint replacement alternatives. Methods A retrospective analysis was conducted using the Merative MarketScan Commercial and Medicare Supplemental databases from January 2018 to December 2023. Patients with a diagnosis of metal hypersensitivity were identified using International Classification of Diseases 10th Edition (ICD-10) codes. Annual incidence was calculated for the general population and for patients undergoing TKA. TKA revision rates were calculated for patients with and without metal hypersensitivity. Secondary analyses assessed the incidence of novel TKA implants that are specifically advertised as "metal sensitive". Results The overall incidence of metal hypersensitivity in the general database population ranged from 0.019% to 0.025%. Patients undergoing TKA demonstrated significantly higher rates of metal allergy diagnosis (p<0.001, annually), with the overall incidence ranging from 0.133% to 0.165%. Non-significant downward trends in the incidence of metal hypersensitivity were noted in both the general and TKA populations. Patients with metal hypersensitivity had TKA revisions at a rate that was significantly higher than those who did not (14.03% vs. 3.15%). (p < 0.001). Patients with a diagnosis of metal allergy represented 0.68% of all revision cases. Seven novel orthopedic implants with explicit "metal sensitive" marketing were released between 2018 - 2025. Conclusion This national database study demonstrates low and stable rates of metal hypersensitivity among both the general and TKA patients. There was no change in the incidence of metal hypersensitivity in either population over time. Patients with metal hypersensitivity represented less than 1% of TKA revisions. These findings challenge the value of medical device development for niche markets.

BACKGROUND:The impact of liver cirrhosis on surgical outcomes is well-known. This study aimed to compare postoperative outcomes of total hip arthroplasty (THA) in patients with versus without cirrhosis. METHODS: = 10). RESULTS: = 0.479) between non-cirrhotic and cirrhotic THA patients at 120 months of follow-up. CONCLUSIONS:Cirrhotic patients, particularly those categorized as moderate-to-severe, undergoing THA may have higher risk of having a readmission or revision for PJI. However, overall 90-day readmission and revision risk were similar between non-cirrhotic and cirrhotic patients. Future research with larger sample sizes and databases is needed to further risk stratify, optimize and counsel cirrhosis patients surrounding THA.